Skip to main content

Branded

  • Novo Nordisk breaks ground on $1.8 billion N.C. production facility

    CLAYTON, N.C. — Novo Nordisk announced Monday that it had broken ground on its new facility where it will produce diabetes medicine. The $1.8 billion facility’s ground breaking event was attended by the company’s president and CEO Lars Rebien Sørensen, as well as N.C. Gov. Pat McCrory and more than 100 employees, policy makers and community members. 
     

  • Apple launches latest patient-friendly tool to manage health

  • Walgreens Flu Index: Flu still trending high

    DEERFIELD, Ill. - Flu activity is still trending high according to the latest Walgreens Flu Index released Thursday. According to the report, Kentucky, Wyoming and New Mexico are the three states exhibiting the most flu activity. Also on that top 10 list is New Jersey and Hawaii. 
     
    The top 10 markets with flu activity for the week of March 20 were: 
     
    1. El Paso, Texas (Las Cruces, N.M.);
    2. Louisville, Ky.;
    3. Beaumont – Port Arthur, Texas;

  • Health Canada reschedules naloxone, makes it available without prescription

    OTTOWA — Pharmacies in Canada can now dispense naloxone to patients without a prescription. Health Canada announced earlier this week that it had revised the Federal Prescription Drug use and reclassified naloxone as a Schedule II drug. 
     

  • Express Scripts: 2015 FDA approvals hit all-time high

    ST. LOUIS — A new analysis by Express Scripts is taking a look at the record-breaking number of drug approvals that came from the Food and Drug Administration in 2015. The company notes that 56 drugs were approved by the FDA last year, a number that topped the previously held record of 53 approvals from 1996. 
     

  • FDA approves Lilly's plaque psoriasis treatment Taltz

    SILVER SPRING, Md. — The Food and Drug Administration announced Tuesday that it had approved Eli Lilly and Co.’s new drug Taltz (ixekizumab). The drug is indicated to treat moderate to severe plaque psoriasis in adults. 
     

  • Teva’s Cinqair gets FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration announced Tuesday that it had approved Teva Pharmaceuticals’ Cinqair (reslizumab). The drug is indicated as maintenance treatment for severe asthma in patients over age 18 alongside other medications. 
     

  • Aprecia announces availability of 3D-printed drug Spritam

    BLUE ASH, Ohio — Aprecia Pharmaceuticals announced the U.S. availability of its Spritam (levetiracetam) tablets on Tuesday. The epilepsy medication is the first tablet made using the company’s ZipDose 3D printing technology to be approved by the Food and Drug Administration. It is designed to dissolve with a sip of liquid, easing the process of taking medication for patients with difficulty swallowing, the company said. 
X
This ad will auto-close in 10 seconds